Cellebrite DI Ltd. SEC filings document its foreign private issuer reporting for an AI-powered digital investigative and intelligence software business. Form 6-K current reports furnish quarterly and annual results releases, GAAP financial tables incorporated by reference into Form S-8 and Form F-3 registration statements, and annual general meeting voting results under the Israeli Companies Law and the company’s articles of association.
The filing record also includes Form 20-F annual reporting, which provides the recurring public-company framework for Cellebrite’s business, financial reporting and ordinary-share governance disclosures.
Cellebrite DI Ltd. Chief Marketing Officer David Nicholas Gee reported a small open-market sale of company shares linked to tax obligations from vested equity awards. He sold 228 ordinary shares at a weighted average price of $13.01 per share, with individual trades ranging from $12.84 to $13.175. These shares originated from restricted stock units granted on February 11, 2025 and were sold to cover associated tax liabilities. After the transaction, Gee directly owned 147,705 ordinary shares, indicating that the sale represented only a minor portion of his overall holdings.
Cellebrite DI Ltd. Global Chief Revenue Officer Marcus Jewell reported an open-market sale of 383 ordinary shares at a weighted average price of $13.01 per share. The footnotes explain the disposition is associated with tax obligations arising from the vesting of previously granted restricted stock units. Following this transaction, Jewell directly holds 452,759 ordinary shares.
Ramji Shiven reported acquisition or exercise transactions in this Form 4 filing.
Cellebrite DI Ltd. reported that President Products & Tech Ramji Shiven received a compensation grant of 423,550 restricted share units (RSUs), each representing one ordinary share when settled. Following this award, he holds 423,550 ordinary shares directly.
The RSUs vest over time: 105,898 vest on May 4, 2027, and 26,471 additional RSUs vest every three months through May 4, 2030, encouraging long-term retention and performance alignment.
Cellebrite DI Ltd. reported strong growth for the first quarter of 2026. Revenue rose to $128.3 million from $107.5 million, driven mainly by subscription services, which increased to $96.5 million. GAAP net income declined to $10.9 million from $17.4 million as operating expenses rose.
On a non-GAAP basis, operating income improved to $28.6 million and adjusted EBITDA increased to $30.6 million, with an adjusted EBITDA margin of 23.9%. The company highlighted annual recurring revenue growth of 21% and a trailing 12‑month free cash flow margin of 32%, reflecting a cash‑generative subscription model.
For the second quarter of 2026, Cellebrite expects ARR of $510–$513 million and revenue of $130–$133 million, with adjusted EBITDA of $29–$31 million. Full‑year 2026 guidance calls for ARR of $567–$573 million, revenue of $565–$571 million, and adjusted EBITDA of $149–$155 million, implying healthy profitability and continued growth.
Cellebrite DI Ltd. filed a Form 144 reporting a proposed resale of 1,045 ordinary shares as vested Restricted Share Units under an S-8 registered plan on 05/11/2026. The filing also lists recent open-market sales by Marcus Jewell of 1,779, 13,276, and 4,613 ordinary shares with trade dates in 02/2026.
Cellebrite DI Ltd. submitted a Form 144 notice reporting proposed sales of ordinary shares and related transactions. The filing lists 653 Restricted Share Units vested under an issuer S-8 registered plan on 05/11/2026 and shows recent sales by an affiliate, David Gee, of 1,165, 2,609, and 4,517 ordinary shares on 02/12/2026, 02/23/2026, and 02/24/2026, respectively.
Cellebrite DI Ltd. submitted a Form 3 identifying Ramji Shiven as an officer with the title President Products & Tech. The filing does not report any share purchases, sales, or other transactions, and shows no derivative positions or holdings data in the provided summary.
Cellebrite DI Ltd. director Yonatan Domnitz filed an initial ownership report showing his equity position in the company. The filing lists 10,601 restricted stock units, each representing a contingent right to receive one ordinary share, vesting on September 17, 2026.
In addition, he holds 60,795 ordinary shares directly after the reported positions. The restricted stock units have an exercise price of $0.0000, indicating they are granted as equity compensation rather than purchased in the market. This Form 3 does not reflect new open-market buying or selling, but establishes his starting ownership as an insider.
Cellebrite DI Ltd. director Utsumi Ryusuke filed an initial statement of beneficial ownership. He reports direct holdings of 40,795 Ordinary Shares and 10,601 Restricted Stock Units, each representing a right to receive one Ordinary Share. The restricted stock units vest on September 17, 2026, reflecting future potential equity ownership rather than a current share issuance.
Cellebrite DI Ltd. Chief People Officer Tadmor-Eilat Zohar reported initial beneficial ownership of the company’s equity. She holds 129,814 Ordinary Shares directly, including multiple blocks of restricted share units and performance share units that vest over time based on service and performance conditions.
She also holds stock options over 22,722 Ordinary Shares at an exercise price of $4.95 per share expiring on February 13, 2033, and options over 28,236 Ordinary Shares at an exercise price of $11.51 per share expiring on March 19, 2034.